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Abstract
Background: Wilson's disease with osseomuscular type is a rare condition, which often lacks typical hepatic and
neurological symptoms and causes misdiagnoses easily. During the past 10 years, eight Chinese patients of
osseomuscular type of Wilson's disease were identified in our clinic.
Methods: Clinical information was gathered from medical records and follow-ups. The genetic testing was
performed in each patient. Serum ceruloplasmin, Kayser-Fleischer rings, liver function, brain magnetic resonance
imaging and abdominal ultrasonography were also evaluated.
Results: The median age of onset is 12 years of age. The patients had their initial musculoskeletal conditions with
arthralgia or joint deformity, while the hepatic or neurologic signs were minimal. Most patients (6/8) eventually
developed clinical neurological symptoms afterwards with a median interval of 36 months. All of them had normal
liver function and low serum ceruloplasmin (<0.1 g/L). Most patients (6/8) present with Kayser-Fleischer rings and
abnormal hepatic ultrasonography. The arthralgia was resolved with copper chelation therapy.
Conclusions: Wilson’s disease with osseomuscular type occurs without typical hepatic or neurological symptoms,
which makes the clinical diagnosis challenging. Serum ceruloplasmin, abdominal ultrasonography, ophthalmic
examination and genetic testing help to establish the diagnosis. Early diagnosis can initiate an effective treatment
and prevent the further damage.
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Background
Wilson’s disease (WD), also known as hepatolenticular de-
generation, is an autosomal recessive disease (incidence 1/
30,000) characterized by Kayser-Fleischer rings of cornea
(K-F rings) and multisystem damage, including liver cir-
rhosis, neurological symptoms and musculoskeletal de-
formity. The disease is caused by mutations in the ATP7B
gene, which encodes a copper-transporting ATPase in the
liver. The deficiency in the enzyme activity can lead to a
toxic copper accumulation in multiple organs, which may
be responsible for its wide variety of symptoms [1].
Despite wide varieties of clinical manifestations, WD
patients typically present with liver dysfunction or
neurological disorders. Musculoskeletal abnormalities,
including premature osteoarthritis, skeletal deformity
and pathological bone fractures, can be occasionally
found in WD patients with hepatic or neurologic type
[2, 3], but very rare as initial symptoms (incidence ~2%
in Chinese population) [4]. These conditions, also
known as “osseomuscular type” of WD, often lack typical
hepatic and neurological symptoms and cause misdiag-
noses easily [5, 6].
During the past 10 years, we have collected and identi-
fied eight Chinese WD patients with osseomuscular type
in our clinic. Their genotypes, clinical manifestations,
biochemical parameters and outcome of treatment are
reported herein, aiming to improve early diagnosis and
therapy with this condition.
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All eight WD patients were diagnosed by genetic testing.
The degree of osseomuscular symptoms was based on
the published assessment scale (0: Normal. 1: Abnormal
skeletal X-ray; asymptomatic.2: Difficulty in ADL but
independent. 3: Requires help in ADL. 4: Dependent on
others for ADL. 5: Fracture or bedbound) [7]. In
addition, ceruloplasmin, K-F rings, liver function, brain
magnetic resonance imaging (MRI) and abdominal ultra-
sonography were also evaluated.
Genotype analysis
Genomic DNA was extracted from peripheral EDTA-
treated blood by Blood Genomic Extraction Kit
(Qiagen, Hilden, Germany). The Sanger sequencing of




All eight patients carried biallelic mutations, and seven
of them were compound heterogeneous (Table 1). The
most frequent mutation was p.R778L (6/16), which was
also the most common mutation of ATB7B in Chinese
population [9].
Clinical manifestation
All of patients denied WD family histories. The median
age of onset is 12 years of age (range 3–17 years). Their
complains were all about musculoskeletal problems such
as arthralgia and joint deformity (Table 1). The abnor-
malities include arthralgia of the knees in four patients,
genu varum in two patients, arthralgia of hip joints in
one patient, genu valgum in one patient and talipse
equinovarus in one patient. The median assessment
score of osseomuscular symptoms is 3 (range 2–4).
As an example, Patient 8 is a 13-year-old boy with a
10-year history of walking difficulty. After a hernia sur-
gery at 3 years of age, he felt knees and ankles sore after
taking a long walk. The condition progressed slowly and
he got a hip pain at 12 years of age. The pain was aggra-
vated by walking and rapidly made him unable to walk
any more. Physical examination revealed a severely lim-
ited movement of bilateral hip joint in lower limbs. The
motion range of his hip joint was only about 25° (flexion
45° to 70°). Excessive extension or flexion would elicit
intense and sharp pain immediately, so the patient could
never straighten his legs. When standing and walking,
he had to keep a “crouching” posture with bent hips,
and steady himself with hands on knees. His condition
had been considered as a rheumatic disease for many
years and diagnosed as “arthralgia” or “osteoarthritis” in
many hospitals. However, the diagnosis was indefinite
and he only received some anti-inflammatory therapy.
Similar to Patient 8, all the other patients also sought
for medical attention in orthopedics or rheumatology
firstly, due to absence of neurological and hepatic symp-
toms. Moreover, four patients (Patient 1, 4, 5, 6) with
deformities subsequently underwent the orthopedic sur-
geries. However, the orthopedic surgery did not correct
the skeletal abnormalities and neurological deterioration
ensued. Patients 1 and 6 showed neurological symptoms
shortly after surgeries (<2 months) and the other two de-
veloped neurological symptoms after 15 and 36 months
respectively (Table 1).
Despite the absence of neurological complaints initially,
it is noteworthy that most patients (6/8) eventually devel-
oped neurological symptoms afterwards with a median
interval of 36 months (range 8–84 months), including
Table 1 Genotype and clinical course in eight cases of WD with osseomuscular type












1 F p.A874V + p.P992L 10 Genu valgum (3) Dysarthria, difficult
with writing, musk face
8 Yes 2
2 M p.M769Hfs*26 +
p.R919G
17 Arthralgia in knee joints (2) Dysarthria, tremor 60 No -
3 M p.R778Q + p.I930del 12 Arthralgia in knee joints (2) Normal - No -
4 F p.E332* + p.R778L 10 Genu varum (3) Dysarthria, bradykinesia 18 Yes 15
5 F p.R778L + p.I1148T 13 Genu varum, femoral head
necrosis, dislocation of the
left shoulder (3)
Tremor 36 Yes 36
6 F p.R778L + p.R778L 15 Talipes equinovarus (3) Tremor writer’s cramp N/A Yes <2
7 M p.R778L + p.G943D 12 Arthralgia in knee joints (4) Tremor, dysarthria 84 No -
8 M p.R778L + p.V1106I 3 Arthralgia in hip and knee
joints, dysplasia of thoracic
vertebrae (4)
Normal N/A No -
*Translation termination codon, O osseomuscular symptoms, N neurological symptom, S surgery, N/A not available
aBased on the published assessment scale for osseomuscular symptoms [7]
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tremor, dysarthria, writing difficulty and bradykinesia
(Table 1). Then it is the moment when most diagnoses of
WD were taken into consideration in these patients. The
interval between the onset of osseomuscular symptoms
and establishment of the diagnosis was at least 10 months
(Patient 1) and could reach as long as 10 years (Patient 8).
The neurological symptoms included tremor in four pa-
tients, dysarthria in four patients, writing difficulty in two
patients and bradykinesia in one patient. Patient 1 also
manifested psychiatric symptoms.
Accessory examination
The K-F ring, known as a specific sign in WD [1], was
present in most patients (6/8) (Table 2). However, since
most patients had developed the neurological symptoms
when examining, the initial rate of K-F rings might be
lower.
Serum ceruloplasmin concentration was less than
0.1 g/L (reference: 0.2–0.4 g/L) in all patients. No signifi-
cant abnormalities in liver function were observed,
including aminotransferase, bilirubin and albumin pa-
rameters. However, the ultrasonography showed features
of chronic hepatic diseases in most patients (6/8)
(Table 2). All the patients were evaluated as Class A
based on Child-Pugh score.
Among the five patients taking the brain MRI, four
showed different degree of abnormal MRI signals.
Abnormal T2 signals were discovered in three cases in
basal ganglia, and two cases in the brain stem (Table 2).
For Patient 8, despite a decreased serum ceruloplasmin
(0.05 g/L), he had no K-F rings, no abnormalities in
brain MRI or hepatic ultrasonography. His X-rays films
showed bilateral hip osteoarthritis (Fig. 1) and knee de-
generative changes (Fig. 2). Notably, the thoracic MRI
incidentally found the dysplasia of thoracic vertebrae
(Fig. 3). Due to the absence of hepatic, neurologic symp-
toms and K-F ring, his diagnosis of WD was confirmed
by genetic testing (Table 1).
Outcome of treatment
After the establishment of diagnosis, all patients received
a copper chelator treatment with D-penicillamine,
dimercaptosuccinic acid (DMSA) or dimercaptopropane
sulfonate (DMPS). No serious related adverse reaction
was observed in these patients. The patients responded
generally well to the therapy. The arthralgia was all re-
solved and neurological symptoms showed different
degrees of improvement (Table 2). However, the im-
provements in bone deformity were minimal.
The Patient 8 improved remarkably by treatment.
After one course of intravenous DMPS (0.25 g q.d. for
6 days) and 3 months of oral DMSA (0.5 g b.i.d.), the pa-
tient felt less painful to move his legs and easier to stand
up from a chair. The physical examination confirmed an
improved movement of his hip joint. The range of mo-
tion was able to reach a degree of 35°, which increased
by 40% compared with the condition 3 months ago.
After 6 month of treatment, the range increased to a










Therapy (Degreea)Strength Tone Reflex
1 + UE & LE 5 UE ↑ (++) <0.02 Basal ganglia Hepatic diffuse disease (9 months after treatment)








(3 months after the treatment)
Pain relieved with improved
speech (0)
3 + UE & LE 5 Normal (++) <0.02 Normal Hepatic diffuse disease,
splenomegaly
(14 months after treatment)
Pain relieved (0)
4 + UE & LE 5 UE & LE ↑ (++) 0.07 N/A Hepatic diffuse disease (after 23 months of inconsecutive
treatment) No obvious
improvement (3)





6 + UE & LE 5 UE & LE ↓ (++) 0.03 N/A Normal N/A
7 + UE 5; pLE 4; dLE 4- UE & LE ↓ Knee (+++) 0.02 N/A Hepatic diffuse disease,
splenomegaly
N/A
8 - UE 4; LE 4- LE ↑ Knee (+++) 0.05 Normal Increased echogenicity (6 months after treatment) Pain
relieved with improved joint
motion (2)
UE upper extremity, LE lower extremity, dLE distal lower extremity, pLE proximal lower extremity, CP ceruloplasmin, N/A not available
aBased on the published assessment scale for osseomuscular symptoms [7]
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degree of 80° and the patient can stand and walk without
the assistance of his hand.
Discussion
WD is one of the limited genetic diseases that can be
clinically cured by timely treatment. The osseomuscular
type of WD begins without typical hepatic and neuro-
logical symptoms, which makes the diagnosis challen-
ging. Most patients are never considered WD until the
neurological symptoms emerged. However, some typical
signs were present in our patients, such as K-F rings or
abnormal liver ultrasonography. Moreover, serum ceru-
loplasmin is a sensitive test in WD patients even without
any hepatic and neurological signs. WD should be highly
suspected when ceruloplasmin is below 0.1 g/L, but
lower levels can also occur with aceruloplasminemia,
renal or enteric protein loss, liver disease and heterozy-
gotes for WD [10]. Therefore, if the patient has a low
serum ceruloplasmin without K-F rings, the diagnosis
should be based on combination of other tests. Genetic
testing is confirmatory and non-invasive, and also con-
venient for screening family members.
The pathogenic mechanisms underlying the musculo-
skeletal damage are not clear. However, it may be a re-
sult of abnormal bone metabolism. Abnormal copper
deposit are found in multiple organs and structures of
WD patients, including the bone, in which the copper
concentration increases about four times [11]. The
radiological changes of arthropathy have been frequently
encountered among WD patients [11–13]. Moreover,
the pathological findings suggested a chronic inflamma-
tory process or degradation of collagen and protein
secondary to a deposition of copper [14]. Besides, the
calcium regulation disorder also makes the bone more
vulnerable to other stimuli, which can result from vita-
min D insufficiency. The hepatic damage in WD can
Fig. 1 The plain film showed hip osteoarthritis with narrowing joint
space, incomplete articular surface and swelling joint capsule (Arrows)
Fig. 2 The knee plain film of knee joints showed degenerative changes
with articular surface hyperosteogeny and swelling joint capsule (Arrows)
Fig. 3 The thoracic MRI showed the dysplasia of thoracic vertebrae,
which had bullet-like shapes with focal cartilage defects at the front
edge (Arrows)
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impede the conversion of vitamin D to its active form,
thus impaired absorption of calcium and led to osteo-
porosis and bone deformity [15]. The similar effects
caused by the damage of kidney and parathyroid gland
in WD patients are also reported [16, 17]. These patho-
logical conditions may be corrected by timely chelation
therapy and hormone supplement.
Dystonia, which is characterized by “sustained or inter-
mittent muscle contractions causing abnormal, often re-
petitive, movements, postures or both”, can develop into
contracture and joint deformity in severe cases [18].
These conditions usually demonstrate spasticity with
markedly increased muscle tone. In our patients, half of
them (Patient 1, 4, 5, 8) had focal or general increase
tones. However, they took 8–36 months to develop the
other neurological symptoms, such as dysarthria, which
usually arose with dystonia in other WD patients. In
addition, Patient 8 never developed any other neuro-
logical signs in his 10-year course, which made it. There-
fore, it remains obscure whether the osseomuscular type
of WD is a result of long-term dystonia or a natural
course of osteopathy.
Conclusions
Although most WD patients with osseomuscular type
will develop neurological symptoms, it is easily misdiag-
nosed when it only manifests as joint pain or bone
deformity. A long-term misdiagnosis may lead to irre-
versible damage to the musculoskeletal system, such as a
permanent deformity, which often requires surgical
intervention and has a poor response to the drug. There-
fore, if a child or adolescent presents with unexplained
musculoskeletal problems, the possibility of WD should
be considered. Serum ceruloplasmin, abdominal ultra-
sonography, ophthalmic examinations and genetic test-
ing will help to establish the diagnosis. Early diagnosis
can initiate an effective treatment and prevent the fur-
ther damage.
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